Robert Jech

List of Publications by Year
in descending order

164	5,162	109137	114278
papers	citations	35 h-index	63 g-index

168	168	168	6184
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Blood DNA methylation provides an accurate biomarker of KMT2B-related dystonia and predicts onset. Brain, 2022, 145, 644-654.	3.7	18
2	Investigating network effects of DBS with fMRI. , 2022, , 275-301.		4
3	WARS2 mutations cause dopa-responsive early-onset parkinsonism and progressive myoclonus ataxia. Parkinsonism and Related Disorders, 2022, 94, 54-61.	1.1	13
4	Tremor associated with similar structural networks in Parkinson's disease and essential tremor. Parkinsonism and Related Disorders, 2022, 95, 28-34.	1.1	7
5	Variants in Mitochondrial <scp>ATP</scp> Synthase Cause Variable Neurologic Phenotypes. Annals of Neurology, 2022, 91, 225-237.	2.8	12
6	Symptom-severity-related brain connectivity alterations in functional movement disorders. NeuroImage: Clinical, 2022, 34, 102981.	1.4	6
7	SPG11: clinical and genetic features of seven Czech patients and literature review. Neurological Research, 2022, , 1-11.	0.6	2
8	Progressive choreodystonia in Xâ€linked <scp>hyperâ€IgM</scp> immunodeficiency: a rare but recurrent presentation. Annals of Clinical and Translational Neurology, 2022, , .	1.7	0
9	Bridging structural and functional biomarkers in functional movement disorder using network mapping. Brain and Behavior, 2022, 12, e2576.	1.0	3
10	Genetic overlap between dystonia and other neurologic disorders: A study of 1,100 exomes. Parkinsonism and Related Disorders, 2022, 102, 1-6.	1.1	8
11	Fosmetpantotenate Randomized Controlled Trial in Pantothenate Kinaseâ€“Associated Neurodegeneration. Movement Disorders, 2021, 36, 1342-1352.	2.2	20
12	SERIALâ€ORDER recall in working memory across the cognitive spectrum of Parkinsonâ€™s disease and neuroimaging correlates. Journal of Neuropsychology, 2021, 15, 88-111.	0.6	5
13	Brittle Biballismâ€Dystonia in a Pediatric Patient with <scp>GNAO1</scp> Mutation Managed Using Pallidal Deep Brain Stimulation. Movement Disorders Clinical Practice, 2021, 8, 153-155.	0.8	5
14	Altered sensorimotor fMRI directed connectivity in Parkinson's disease patients. European Journal of Neuroscience, 2021, 53, 1976-1987.	1.2	6
15	A Neurodevelopmental Disorder With Dystonia and Chorea Resulting From Clustering <scp>CAMK4</scp> Variants. Movement Disorders, 2021, 36, 520-521.	2.2	5
16	<scp>JuSpace</scp>: A tool for spatial correlation analyses of magnetic resonance imaging data with nuclear imaging derived neurotransmitter maps. Human Brain Mapping, 2021, 42, 555-566.	1.9	95
17	De novo variants in neurodevelopmental disordersâ€”experiences from a tertiary care center. Clinical Genetics, 2021, 100, 14-28.	1.0	64
18	Variant recurrence confirms the existence of a FBXO31â€related spasticâ€dystonic cerebral palsy syndrome. Annals of Clinical and Translational Neurology, 2021, 8, 951-955.	1.7	6

#	Article	IF	Citations
19	Clinically relevant copy-number variants in exome sequencing data of patients with dystonia. Parkinsonism and Related Disorders, 2021, 84, 129-134.	1.1	15
20	Myoclonic dystonia phenotype related to a novel calmodulin-binding transcription activator 1 sequence variant. Neurogenetics, 2021, 22, 137-141.	0.7	3
21	Concomitant Medication Usage with <scp>Levodopaâ€Carbidopa</scp> Intestinal Gel: Results from the <scp>COSMOS</scp> Study. Movement Disorders, 2021, 36, 1853-1862.	2.2	24
22	A Recurrent <scp>VPS16</scp> p.Arg187* Nonsense Variant in Earlyâ€Onset Generalized Dystonia. Movement Disorders, 2021, 36, 1984-1985.	2.2	7
23	Trisomy X syndrome with dystonia and a pathogenic SATB1 variant. Neurological Sciences, 2021, 42, 3883-3884.	0.9	1
24	Scoring Algorithmâ€Based Genomic Testing in Dystonia: A Prospective Validation Study. Movement Disorders, 2021, 36, 1959-1964.	2.2	7
25	Guided Self-rehabilitation Contracts Combined With AbobotulinumtoxinA in Adults With Spastic Paresis. Journal of Neurologic Physical Therapy, 2021, Publish Ahead of Print, 203-213.	0.7	2
26	Dystonia Management: What to Expect From the Future? The Perspectives of Patients and Clinicians Within DystoniaNet Europe. Frontiers in Neurology, 2021, 12, 646841.	1.1	10
27	Expiratory muscle strength training in Parkinson's disease patients: a pilot study of mobile monitoring application. Movement Disorders Clinical Practice, 2021, 8, 1148-1149.	0.8	3
28	Pathogenic SPTBN1 variants cause an autosomal dominant neurodevelopmental syndrome. Nature Genetics, 2021, 53, 1006-1021.	9.4	44
29	Dystonia as a prominent presenting feature in developmental and epileptic encephalopathies: A case series. Parkinsonism and Related Disorders, 2021, 90, 73-78.	1.1	9
30	The sensitivity of ECG contamination to surgical implantation site in brain computer interfaces. Brain Stimulation, 2021, 14, 1301-1306.	0.7	43
31	Asymmetry of the insulaâ€sensorimotor circuit in Parkinson's disease. European Journal of Neuroscience, 2021, 54, 6267-6280.	1.2	8
32	Severely disabled multiple sclerosis patients can achieve the performance of healthy subjects after expiratory muscle strength training. Multiple Sclerosis and Related Disorders, 2021, 55, 103187.	0.9	4
33	When can maximal efficacy occur with repeat botulinum toxin injection in upper limb spastic paresis?. Brain Communications, 2021, 3, fcaa201.	1.5	7
34	Determining a Short Form Montreal Cognitive Assessment (s-MoCA) Czech Version: Validity in Mild Cognitive Impairment Parkinsonâ€™s Disease and Cross-Cultural Comparison. Assessment, 2020, 27, 1960-1970.	1.9	16
35	Validation of the Freezing of Gait Questionnaire in patients with Parkinsonâ€™s disease treated with deep brain stimulation. Neurological Sciences, 2020, 41, 1133-1138.	0.9	5
36	Disentangling brain functional network remodeling in corticobasal syndrome â€“ A multimodal MRI study. NeuroImage: Clinical, 2020, 25, 102112.	1.4	10

#	Article	IF	Citations
37	Monogenic variants in dystonia: an exome-wide sequencing study. Lancet Neurology, The, 2020, 19, 908-918.	4.9	139
38	Severe paroxysmal dyskinesias without epilepsy in a RHOBTB2 mutation carrier. Parkinsonism and Related Disorders, 2020, 77, 87-88.	1.1	9
39	Recessive null-allele variants in MAG associated with spastic ataxia, nystagmus, neuropathy, and dystonia. Parkinsonism and Related Disorders, 2020, 77, 70-75.	1.1	3
40	Test the Best: Classification Accuracies of Four Cognitive Rating Scales for Parkinsonâ€™s Disease Mild Cognitive Impairment. Archives of Clinical Neuropsychology, 2020, 35, 1069-1077.	0.3	15
41	Brief Visuospatial Memory Test-Revised: normative data and clinical utility of learning indices in Parkinsonâ€™s disease. Journal of Clinical and Experimental Neuropsychology, 2020, 42, 1099-1110.	0.8	7
42	Differential effects of deep brain stimulation and levodopa on brain activity in Parkinsonâ€™s disease. Brain Communications, 2020, 2, fcaa005.	1.5	18
43	Lossâ€ofâ€Function Variants in <scp>HOPS</scp> Complex Genes <scp>VPS16</scp> and <scp>VPS41</scp> Cause Early Onset Dystonia Associated with Lysosomal Abnormalities. Annals of Neurology, 2020, 88, 867-877.	2.8	70
44	3D visual cueing shortens the double support phase of the gait cycle in patients with advanced Parkinson's disease treated with DBS of the STN. PLoS ONE, 2020, 15, e0244676.	1.1	3
45	Impact of dopamine and cognitive impairment on neural reactivity to facial emotion in Parkinson's disease. European Neuropsychopharmacology, 2019, 29, 1258-1272.	0.3	20
46	Clinical course of patients with pantothenate kinase-associated neurodegeneration (PKAN) before and after DBS surgery. Journal of Neurology, 2019, 266, 2962-2969.	1.8	11
47	Recessive variants in ZNF142 cause a complex neurodevelopmental disorder with intellectual disability, speech impairment, seizures, and dystonia. Genetics in Medicine, 2019, 21, 2532-2542.	1.1	17
48	Unraveling corticobasal syndrome and alien limb syndrome with structural brain imaging. Cortex, 2019, 117, 33-40.	1.1	17
49	Topography of emotional valence and arousal within the motor part of the subthalamic nucleus in Parkinsonâ€™s disease. Scientific Reports, 2019, 9, 19924.	1.6	5
50	Cerebrospinal Fluid Leak to the IPG Subcutaneous Pocket after Deep Brain Stimulation Implantation: A Case Report. Stereotactic and Functional Neurosurgery, 2019, 97, 404-406.	0.8	1
51	Regional gray matter changes and age predict individual treatment response in Parkinson's disease. NeuroImage: Clinical, 2019, 21, 101636.	1.4	18
52	Prevalence and evolution of spasticity in patients suffering from firstâ€ever stroke with carotid origin: a prospective, longitudinal study. European Journal of Neurology, 2019, 26, 880-886.	1.7	20
53	Effect of pallidal deep-brain stimulation on articulation rate in dystonia. Neurological Sciences, 2019, 40, 869-873.	0.9	1
54	Modulatory Effects of Levodopa on Cerebellar Connectivity in Parkinsonâ€™s Disease. Cerebellum, 2019, 18, 212-224.	1.4	16

#	Article	IF	Citations
55	Memory impairment in Parkinsonâ€™s disease: The retrieval versus associative deficit hypothesis revisited and reconciled.. Neuropsychology, 2019, 33, 391-405.	1.0	20
56	Identification of Microrecording Artifacts with Wavelet Analysis and Convolutional Neural Network: An Image Recognition Approach. Measurement Science Review, 2019, 19, 222-231.	0.6	7
57	Reshaping cortical activity with subthalamic stimulation in Parkinson's disease during finger tapping and gait mapped by near infrared spectroscopy. Journal of Applied Biomedicine, 2019, 17, 157-166.	0.6	4
58	System for Motor Evoked Potentials Acquisition and Analysis. IFMBE Proceedings, 2019, , 87-91.	0.2	0
59	Dualistic effect of pallidal deep brain stimulation on motor speech disorders in dystonia. Brain Stimulation, 2018, 11, 896-903.	0.7	7
60	Mild cognitive impairment disrupts attention network connectivity in Parkinson's disease: A combined multimodal MRI and meta-analytical study. Neuropsychologia, 2018, 112, 105-115.	0.7	31
61	Doseâ€Dependent Effects of AbobotulinumtoxinA (Dysport) on Spasticity and Active Movements in Adults With Upper Limb Spasticity: Secondary Analysis of a Phase 3 Study. PM and R, 2018, 10, 1-10.	0.9	12
62	Ataxia Telangiectasia Gene Mutation in Isolated Segmental Dystonia Without Ataxia and Telangiectasia. Movement Disorders Clinical Practice, 2018, 5, 89-91.	0.8	11
63	Benefits of pallidal stimulation in dystonia are linked to cerebellar volume and cortical inhibition. Scientific Reports, 2018, 8, 17218.	1.6	9
64	Microelectrode Neuronal Activity Biomarker of the Internal Globus Pallidus in Dystonia Correlates with Long-term Neuromodulation Effects. , 2018, , .		1
65	Unraveling connectivity changes due to dopaminergic therapy in chronically treated Parkinsonâ€™s disease patients. Scientific Reports, 2018, 8, 14328.	1.6	18
66	KMT2B Is Selectively Required for Neuronal Transdifferentiation, and Its Loss Exposes Dystonia Candidate Genes. Cell Reports, 2018, 25, 988-1001.	2.9	28
67	A unique de novo gain-of-function variant inCAMK4associated with intellectual disability and hyperkinetic movement disorder. Journal of Physical Education and Sports Management, 2018, 4, a003293.	0.5	16
68	Brain connectivity changes when comparing effects of subthalamic deep brain stimulation with levodopa treatment in Parkinson's disease. NeuroImage: Clinical, 2018, 19, 1025-1035.	1.4	43
69	Early manifestation of spasticity after first stroke in the territory of the internal carotid artery. A prospective multicenter study. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2018, 162, 319-323.	0.2	2
70	Frequency-phase analysis of resting-state functional MRI. Scientific Reports, 2017, 7, 43743.	1.6	18
71	A parsimonious scoring and normative calculator for the Parkinsonâ€™s disease mild cognitive impairment battery. Clinical Neuropsychologist, 2017, 31, 1231-1247.	1.5	11
72	A Comparative Study of Tower of London Scoring Systems and Normative Data. Archives of Clinical Neuropsychology, 2017, 32, 328-338.	0.3	17

#	Article	IF	Citations
73	KMT2B rare missense variants in generalized dystonia. Movement Disorders, 2017, 32, 1087-1091.	2.2	42
74	Efficacy and Safety of AbobotulinumtoxinA (Dysport) for the Treatment of Hemiparesis in Adults With Upper Limb Spasticity Previously Treated With Botulinum Toxin: Subanalysis From a Phase 3 Randomized Controlled Trial. PM and R, 2017, 9, 1181-1190.	0.9	17
75	Clinimetric validity of the Trail Making Test Czech version in Parkinsonâ€™s disease and normative data for older adults. Clinical Neuropsychologist, 2017, 31, 42-60.	1.5	12
76	Comparative analysis of speech impairment and upper limb motor dysfunction in Parkinsonâ€™s disease. Journal of Neural Transmission, 2017, 124, 463-470.	1.4	15
77	Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry. Parkinsonism and Related Disorders, 2017, 45, 13-20.	1.1	149
78	Molecular diversity of combined and complex dystonia: insights from diagnostic exome sequencing. Neurogenetics, 2017, 18, 195-205.	0.7	37
79	Separate neural representations of depression, anxiety and apathy in Parkinsonâ€™s disease. Scientific Reports, 2017, 7, 12164.	1.6	49
80	Methods for automatic detection of artifacts in microelectrode recordings. Journal of Neuroscience Methods, 2017, 290, 39-51.	1.3	18
81	Frontal Assessment Battery in Parkinsonâ€™s Disease: Validity and Morphological Correlates. Journal of the International Neuropsychological Society, 2017, 23, 675-684.	1.2	19
82	General and selective brain connectivity alterations in essential tremor: A resting state fMRI study. NeuroImage: Clinical, 2017, 16, 468-476.	1.4	29
83	Efficacy and safety of abobotulinumtoxinA in spastic lower limb. Neurology, 2017, 89, 2245-2253.	1.5	79
84	The Diagnostic Accuracy of Parkinson's Disease Mild Cognitive Impairment Battery Using the Movement Disorder Society Task Force Criteria. Movement Disorders Clinical Practice, 2017, 4, 237-244.	0.8	19
85	Motion and emotion: anxietyâ€“axial connections in Parkinsonâ€™s disease. Journal of Neural Transmission, 2017, 124, 369-377.	1.4	12
86	Disease-Specific Regions Outperform Whole-Brain Approaches in Identifying Progressive Supranuclear Palsy: A Multicentric MRI Study. Frontiers in Neuroscience, 2017, 11, 100.	1.4	10
87	Diffusion tensor imaging in the characterization of multiple system atrophy. Neuropsychiatric Disease and Treatment, 2016, Volume 12, 2181-2187.	1.0	13
88	Improvement of active movement and function in adults with chronic spastic paresis following repeated treatment with abobotulinumtoxina (DysportÂ®). Toxicon, 2016, 123, S34-S35.	0.8	3
89	Probabilistic Model of Neuronal Background Activity in Deep Brain Stimulation Trajectories. Lecture Notes in Computer Science, 2016, , 97-111.	1.0	2
90	Pallidal stimulation in dystonia affects cortical but not spinal inhibitory mechanisms. Journal of the Neurological Sciences, 2016, 369, 19-26.	0.3	8

#	Article	IF	Citations
91	Tests of manual dexterity and speed in Parkinsonâ€™s disease: Not all measure the same. Parkinsonism and Related Disorders, 2016, 28, 118-123.	1.1	32
92	Paroxysmal exercise-induced dystonia within the phenotypic spectrum ofECHS1deficiency. Movement Disorders, 2016, 31, 1041-1048.	2.2	58
93	http://www.csnn.eu/en/czech-slovak-neurology-article/validity-study-of-the-boston-naming-test-czech-version-58260. Ceska A Slovenska Neurologie A Neurochirurgie, 2016, 79/112, 307-316.	0.0	13
94	Comprehensive Care of Patients with Spastic Paresis â€“ A Long-Term Commitment. European Neurological Review, 2016, 11, 1b.	0.5	0
95	Supervised segmentation of microelectrode recording artifacts using power spectral density. , 2015, 2015, 1524-7.		4
96	Optimization of Parkinson Disease treatment combining anti-Parkinson drugs and deep brain stimulation using patient diaries. , 2015, 2015, 3444-7.		6
97	Chronic stress-like syndrome as a consequence of medial site subthalamic stimulation in Parkinson's disease. Psychoneuroendocrinology, 2015, 52, 302-310.	1.3	20
98	Clinical Validity of the Mattis Dementia Rating Scale in Differentiating Mild Cognitive Impairment in Parkinson's Disease and Normative Data. Dementia and Geriatric Cognitive Disorders, 2015, 39, 303-311.	0.7	23
99	Fast vergence eye movements are disrupted in Parkinson's disease: A video-oculography study. Parkinsonism and Related Disorders, 2015, 21, 797-799.	1.1	27
100	Distinct populations of neurons respond to emotional valence and arousal in the human subthalamic nucleus. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 3116-3121.	3.3	48
101	Resting-state functional magnetic resonance imaging of the subthalamic microlesion and stimulation effects in Parkinson's disease: Indications of a principal role of the brainstem. NeuroImage: Clinical, 2015, 9, 264-274.	1.4	46
102	Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomised controlled trial. Lancet Neurology, The, 2015, 14, 992-1001.	4.9	174
103	Correlation between Relaxometry and Diffusion Tensor Imaging in the Globus Pallidus of Huntingtonâ€™s Disease Patients. PLoS ONE, 2015, 10, e0118907.	1.1	20
104	Predicting Falls in Parkinson Disease: What Is the Value of Instrumented Testing in OFF Medication State?. PLoS ONE, 2015, 10, e0139849.	1.1	34
105	Acute Hyperkinetic Syndromes Treated with Stereotactic Neurosurgery Intervention â€“â€Š â€˙Three Case Reports. Ceska A Slovenska Neurologie A Neurochirurgie, 2015, 78/111, 591-596.	0.0	0
106	Eye Movements in Ephedrone-Induced Parkinsonism. PLoS ONE, 2014, 9, e104784.	1.1	15
107	7â€Tesla <scp>Magnetic Resonance Imaging</scp> for Brain Iron Quantification in Homozygous and Heterozygous <scp>PANK</scp>2 Mutation Carriers. Movement Disorders Clinical Practice, 2014, 1, 329-335.	0.8	15
108	Grooved Pegboard Predicates More of Cognitive Than Motor Involvement in Parkinsonâ€™s Disease. Assessment, 2014, 21, 723-730.	1.9	35

#	Article	IF	Citations
109	Disorders of Balance and Gait in Essential Tremor Are Associated with Midline Tremor and Age. Cerebellum, 2013, 12, 27-34.	1.4	61
110	Levodopa increases functional connectivity in the cerebellum and brainstem in Parkinsonâ€™s disease. Brain, 2013, 136, e234-e234.	3.7	34
111	Sex, Food and Threat: Startling Changes after Subthalamic Stimulation in Parkinson's Disease. Brain Stimulation, 2013, 6, 740-745.	0.7	18
112	Motor Matters: Tackling Heterogeneity of Parkinsonâ€™s Disease in Functional MRI Studies. PLoS ONE, 2013, 8, e56133.	1.1	10
113	Basal Ganglia Neuronal Activity during Scanning Eye Movements in Parkinsonâ€™s Disease. PLoS ONE, 2013, 8, e78581.	1.1	13
114	Decrease in Blood Cortisol Corresponds to Weight Gain following Deep Brain Stimulation of the Subthalamic Nucleus in Parkinsonâ€™s Disease. Stereotactic and Functional Neurosurgery, 2012, 90, 410-411.	0.8	15
115	Cortical pattern of complex but not simple movements is affected in writerâ€™s cramp: A parametric event-related fMRI study. Clinical Neurophysiology, 2012, 123, 755-763.	0.7	16
116	Wrapper feature selection for small sample size data driven by complete error estimates. Computer Methods and Programs in Biomedicine, 2012, 108, 138-150.	2.6	15
117	Accounting for Movement Increases Sensitivity in Detecting Brain Activity in Parkinson's Disease. PLoS ONE, 2012, 7, e36271.	1.1	9
118	A Loud Auditory Stimulus Overcomes Voluntary Movement Limitation in Cervical Dystonia. PLoS ONE, 2012, 7, e46586.	1.1	5
119	The Subthalamic Microlesion Story in Parkinson's Disease: Electrode Insertion-Related Motor Improvement with Relative Cortico-Subcortical Hypoactivation in fMRI. PLoS ONE, 2012, 7, e49056.	1.1	51
120	Performance comparison of extracellular spike sorting algorithms for single-channel recordings. Journal of Neuroscience Methods, 2012, 203, 369-376.	1.3	64
121	Does WOQ-9 help to recognize symptoms of non-motor wearing-off in Parkinsonâ€™s disease?. Journal of Neural Transmission, 2012, 119, 373-380.	1.4	14
122	Abnormal Activity in the Precuneus during Time Perception in Parkinson's Disease: An fMRI Study. PLoS ONE, 2012, 7, e29635.	1.1	34
123	Weight Gain Is Associated with Medial Contact Site of Subthalamic Stimulation in Parkinson's Disease. PLoS ONE, 2012, 7, e38020.	1.1	27
124	DYT 6-A novel THAP1 mutation with excellent effect on pallidal DBS. Movement Disorders, 2011, 26, 924-925.	2.2	20
125	Sleep disturbances in untreated Parkinsonâ€™s disease. Journal of Neurology, 2011, 258, 2254-2259.	1.8	40
126	Quantitative brain MR imaging in amyotrophic lateral sclerosis. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2011, 24, 67-76.	1.1	10

#	Article	IF	Citations
127	Pallidal stimulation in siblings with pantothenate kinaseâ€associated neurodegeneration: Fourâ€year followâ€up. Movement Disorders, 2011, 26, 184-187.	2.2	34
128	Subthalamic nucleus stimulation affects incentive salience attribution in Parkinson's disease. Movement Disorders, 2011, 26, 2260-2266.	2.2	42
129	Hormonal regulators of food intake and weight gain in Parkinson's disease after subthalamic nucleus stimulation. Neuroendocrinology Letters, 2011, 32, 437-41.	0.2	29
130	Effects of Ropinirole Prolonged-Release on Sleep Disturbances and Daytime Sleepiness in Parkinson Disease. Clinical Neuropharmacology, 2010, 33, 186-190.	0.2	36
131	Dystonia in neurodegeneration with brain iron accumulation: outcome of bilateral pallidal stimulation. Brain, 2010, 133, 701-712.	3.7	212
132	Repetitive TMS of the somatosensory cortex improves writer's cramp and enhances cortical activity. Neuroendocrinology Letters, 2010, 31, 73-86.	0.2	42
133	Efficacy of repetitive transcranial magnetic stimulation for the treatment of refractory chronic tinnitus: a randomized, placebo controlled study. Neuroendocrinology Letters, 2010, 31, 238-49.	0.2	46
134	Beneficial effect of deep brain stimulation of GPi in a patient with dystoniaâ€deafness phenotype. Movement Disorders, 2009, 24, 465-466.	2.2	16
135	Deep brain stimulation in acute management of status dystonicus. Movement Disorders, 2009, 24, 2291-2292.	2.2	43
136	Validity of primary motor area localization with fMRI versus electric cortical stimulation: A comparative study. Acta Neurochirurgica, 2009, 151, 1071-1080.	0.9	55
137	Abnormal corticospinal tract modulation of the soleus H reflex in patients with pure spastic paraparesis. Neuroscience Letters, 2008, 437, 15-19.	1.0	24
138	Functional Imaging of Deep Brain Stimulation: fMRI, SPECT, and PET. , 2008, , 179-201.		9
139	Tremor magnitude: A single index to assess writing and drawing in essential tremor. Parkinsonism and Related Disorders, 2007, 13, 250-253.	1.1	9
140	MR relaxometry in Huntington's disease: Correlation between imaging, genetic and clinical parameters. Journal of the Neurological Sciences, 2007, 263, 20-25.	0.3	43
141	Variation of selective gray and white matter atrophy in Huntington's disease. Movement Disorders, 2007, 22, 1783-1789.	2.2	42
142	Increase in body weight is a non-motor side effect of deep brain stimulation of the subthalamic nucleus in Parkinson's disease. Neuroendocrinology Letters, 2007, 28, 21-5.	0.2	34
143	Deep brain stimulation of the subthalamic nucleus affects resting EEG and visual evoked potentials in Parkinson's disease. Clinical Neurophysiology, 2006, 117, 1017-1028.	0.7	55
144	Reply: Hemiparkinsonism and levodopa-induced dyskinesias following focal nigral lesion. Movement Disorders, 2006, 21, 2268-2268.	2.2	24

#	Article	IF	Citations
145	Cumulative blood oxygenation-level-dependent signal changes support the â€˜time accumulatorâ€™ hypothesis. NeuroReport, 2005, 16, 1467-1471.	0.6	37
146	Hemiparkinsonism and levodopa-induced dyskinesias after focal nigral lesion. Movement Disorders, 2005, 20, 759-762.	2.2	21
147	Retrospective evaluation of the dose of dysport and BOTOX in the management of cervical dystonia and blepharospasm: The REAL DOSE study. Movement Disorders, 2005, 20, 937-944.	2.2	113
148	The role of functional neuronavigation in the treatment of lesions in eloquent areas of the brain. International Congress Series, 2004, 1259, 389-395.	0.2	0
149	Reply: fMRI during deep brain stimulation. Movement Disorders, 2003, 18, 461-462.	2.2	4
150	VIM thalamic stimulation for tremor in a patient with IgM paraproteinaemic demyelinating neuropathy. Movement Disorders, 2003, 18, 1192-1195.	2.2	36
151	Sleep Disturbances and Hypocretin Deficiency in Niemann-Pick Disease Type C. Sleep, 2003, 26, 427-430.	0.6	104
152	Investigation of non-linear properties of multichannel EEG in the early stages of Parkinson's disease. Clinical Neurophysiology, 2001, 112, 38-45.	0.7	86
153	Colour discrimination impairment is not a reliable early marker of Parkinson's disease. Journal of Neurology, 2001, 248, 975-978.	1.8	20
154	Functional magnetic resonance imaging during deep brain stimulation: A pilot study in four patients with Parkinson's disease. Movement Disorders, 2001, 16, 1126-1132.	2.2	153
155	Electromagnetic field of mobile phones affects visual event related potential in patients with narcolepsy. Bioelectromagnetics, 2001, 22, 519-528.	0.9	30
156	Efficacy and safety of a standardised 500 unit dose of Dysport Â® (Clostridium botulinum toxin type A) Tj ETQq0 0 0 rgBT /Overlock 10 T multicentre, randomised, double-blind, placebo-controlled, parallel group study. Journal of Neurology, 2001, 248, 1073-1078.	1.8	79
157	Electromagnetic field of mobile phones affects visual event related potential in patients with narcolepsy. Bioelectromagnetics, 2001, 22, 519-528.	0.9	1
158	Subhypnotic doses of zolpidem oppose dopaminergic-induced dyskinesia in Parkinson's disease. Movement Disorders, 2000, 15, 734-735.	2.2	38
159	Amantadine infusion in treatment of motor fluctuations and dyskinesias in Parkinson's disease. Journal of Neural Transmission, 2000, 107, 1297-1306.	1.4	32
160	Dose-Dependent Reduction of Cerebral Blood Flow During Rapid-Rate Transcranial Magnetic Stimulation of the Human Sensorimotor Cortex. Journal of Neurophysiology, 1998, 79, 1102-1107.	0.9	224
161	Transcranial Magnetic Stimulation during Positron Emission Tomography: A New Method for Studying Connectivity of the Human Cerebral Cortex. Journal of Neuroscience, 1997, 17, 3178-3184.	1.7	657
162	Spatial and nonspatial memory involvement in myasthenia gravis. Journal of Neurology, 1997, 244, 529-532.	1.8	15

#	Article	IF	Citations
163	Brain stem auditory evoked potentials reflect central nervous system involvement in myasthenia gravis. Journal of Neurology, 1996, 243, 547-550.	1.8	11
164	The Instrumental Activities of Daily Living in Parkinsonâ€™s Disease Patients Treated by Subthalamic Deep Brain Stimulation. Frontiers in Aging Neuroscience, 0, 14, .	1.7	2